BCIQ Profiles

Company Profile Report

Consonance, Jay Mohr partner to invest in deprioritized therapeutics

Through a collaboration with biotech executive Jay Mohr, Consonance Capital Partners plans to make its first therapeutics investments out of its $500 million private

Read the full 243 word article

How to gain access

Continue reading with a
two-week free trial.